‘Breakthrough’ Drugs Get ‘Road-MaPP’ – Complete With Communication Timetable
This article was originally published in The Pink Sheet Daily
Executive Summary
CDER Manual of Policy and Procedures describes specific actions FDA review staff will take once a product has received “breakthrough therapy” designation, with an emphasis on more meetings, more frequently.
You may also be interested in...
Surge In Applications Triggers User Fee Inflation
With full NDA and BLA submissions to FDA now growing faster than INDs and supplements, user fees are increasing more rapidly as well.
Breakthrough Designation Is A Two-Way Street, FDA Cautions Sponsors
Sponsors of would-be breakthrough therapies need to move as quickly as FDA is acting, from responding to emails to ramping up manufacturing so they can start trials earlier.
REMS, ‘Breakthrough’ Meetings Get ‘Type B’ Tag In Revised FDA Guidance
In other modifications, FDA tells sponsors seeking Type A meetings – the most urgent category – that data packages must accompany the request.